

Liflow[®], a solution dedicated to oncology imaging, wins the JFR 2024 Innovation Prize in the “Healthcare IT and AI” category

Montpellier, France, September 30th, 2024, at 17H45 CEST

Intrasense (FR0011179886 - ALINS), a specialist in medical imaging software solutions and the developer of Myrian[®] and Liflow[®], is proud to announce that its Liflow[®] solution has been awarded the Prix Innovation JFR (Journées Francophones de la Radiologie) 2024 in the “Healthcare IT and AI” category.

An innovative oncology imaging platform

Developed in close collaboration with radiologists who are experts in oncology imaging, Liflow[®] is a solution designed to meet the growing demands of oncology follow-up. It provides practitioners with a set of innovative tools for automated detection, follow-up and evaluation of tumour lesions on CT-CAP (chest-abdomen-pelvis), the benchmark examination for diagnosing and follow-up for cancer patients.

Liflow[®] combines the results of multi-organ artificial intelligence algorithms and patient progress follow-up indicators in a single image, to improve diagnostic efficiency and accuracy in oncology imaging. The solution has now been enhanced with a lung AI, dedicated to helping diagnose lung cancer. Version 2.0 of the Liflow[®] solution will also incorporate a liver AI developed in partnership with Guerbet, designed for the automated detection, segmentation and measurement of focal liver lesions.

A prestigious award for Liflow[®]

The JFR Innovation Awards, introduced in 2021 by the “Société Française de Radiologie” (SFR), are intended to highlight the achievements of industrial partners who are developing innovations in the field of medical imaging. Organised in collaboration with SNITEM (Syndicat National de l'Industrie des Technologies Médicales) and other major players in the sector, the prize is a marker of technological excellence, awarded in five categories.

Liflow[®] was rewarded in the “Healthcare IT and AI” category for its innovative diagnosis and follow-up capabilities for cancer patients, positioning it as the benchmark solution for oncology imaging. The platform stands out for its patient-centred approach and innovative tools integrated within a unified interface, optimising the quality of care and the efficiency of healthcare professionals. It is fully in line with the digital transformation of oncology follow-up and encourages collaboration between multidisciplinary teams.

Recognition of Intrasense's technological excellence

The JFR 2024 Innovation Award also recognises the Intrasense group's commitment to pushing back the boundaries of medical technology by developing solutions that address today's oncology challenges. In awarding Liflow[®], the SFR is recognising a solution that offers decisive advances in diagnostic assistance and improved oncology treatments, thereby contributing directly to better patient care.

Alexandre Salvador, CEO of Intrasense: "This award is recognition of Intrasense's ability to innovate and provide concrete solutions to the current challenges in oncology medical imaging. With Liflow[®], we are developing a solution that integrates cutting-edge AI algorithms to support radiologists in their daily practice and enhance the accuracy of their diagnoses. Thanks to our dedicated solution, CAP scan interpretation time can be considerably reduced, making a real difference to patient care. Winning the Innovation Prize confirms our ambition to improve the quality of care while optimising the efficiency of practitioners."

About Intrasense

A French expert in medical imaging since 2004, Intrasense develops and markets in 40 countries software platforms that facilitate and secure diagnosis, decision-making and therapeutic follow-up.

Myrian[®], an advanced visualisation solution for radiology, provides 1,200 healthcare establishments with clinical applications to help interpret all types of images. Since 2021, Intrasense has been developing Liflow[®], a new multidisciplinary and collaborative platform dedicated to oncology, to optimise patient care and follow-up.

A subsidiary of the Guerbet Group since June 2023, Intrasense continues to enhance its solutions by integrating artificial intelligence algorithms in medical imaging. Its teams work closely with healthcare professionals to help save lives.

More information at www.intrasense.fr

Intrasense

Salomé Sylvestre
Communications Officer
Phone: +334 67 13 01 30

investisseurs@intrasense.fr

NewCap

Thomas Grojean
Financial communications
and investor relations
Phone: +331 44 71 20 40

intrasense@newcap.eu